# Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

> **NCT03060980** · PHASE3 · TERMINATED · sponsor: **Intarcia Therapeutics** · enrollment: 245 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** ITCA 650 20/60 mcg/day
- **DRUG:** Empagliflozin (oral)
- **DRUG:** Glimepiride (oral)

## Key facts

- **NCT ID:** NCT03060980
- **Lead sponsor:** Intarcia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-03
- **Primary completion:** 2018-01-26
- **Final completion:** 2018-01-26
- **Target enrollment:** 245 (ACTUAL)
- **Why stopped:** Decision by Sponsor
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03060980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03060980, "Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03060980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*